X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2021 16:01 ET
|
X4 Pharmaceuticals
BOSTON, July 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
June 11, 2021 03:00 ET
|
X4 Pharmaceuticals
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström’s patients; meaningful increases in hemoglobin...
X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia
May 26, 2021 08:00 ET
|
X4 Pharmaceuticals
Poster presentation by lead author Dr. Steven Treon available on the EHA website Friday, June 11, 2021 at 9:00 am CET/3:00 am ET Conference call and webcast with poster co-author Dr. Christian Buske...
X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences
May 17, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract
May 12, 2021 10:00 ET
|
X4 Pharmaceuticals
Initial data from first cohort of patients indicate mavorixafor plus ibrutinib to be well tolerated, with encouraging decreases in serum IgM observed These and additional preliminary Phase 1b data to...
X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
May 06, 2021 08:00 ET
|
X4 Pharmaceuticals
Company continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications Enrollment update on Phase 3 WHIM trial expected in...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2021 16:01 ET
|
X4 Pharmaceuticals
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021
April 22, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2021 16:05 ET
|
X4 Pharmaceuticals
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...